CureVac N.V. (CVAC)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
CVAC Chart
CureVac: The Hidden Value Of The mRNA Wallet
CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech, value derives from research quality, patent strength, and clinical success probability, not current revenues. CVAC boasts over 25 years of research and nearly 1,000 mRNA patents, highlighting its intellectual property strength.
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
CureVac Stock Soars on BioNTech Buyout
Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.
CureVac N.V. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 120 | $4 | $4 | - | - |
CureVac N.V. (CVAC) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
CureVac N.V. Profile
| Biotechnology Industry | Healthcare Sector | Alexander Zehnder CEO | NASDAQ (NMS) Exchange | N2451R105 CUSIP |
| DE Country | 825 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CureVac N.V. is a pioneering biopharmaceutical company rooted in Tübingen, Germany, established in the year 2000. The company is committed to the advancement of transformative medicines through the innovative use of messenger ribonucleic acid (mRNA) technology. CureVac N.V. is on the forefront of developing mRNA-based therapeutics and vaccines aimed at addressing a wide array of diseases, ranging from infectious diseases to cancer.
Products and Services
- CV2CoV - A prophylactic vaccine candidate in Phase 1 clinical trial targeting SARS-CoV-2. This represents CureVac's endeavor to contribute to the global fight against COVID-19 by leveraging its mRNA platform to develop a vaccine that could potentially offer immunity against the virus.
- CV7202 - Another vaccine candidate, currently in Phase 1 clinical trial, is aimed at the prevention of rabies. This exemplifies CureVac's application of mRNA technology beyond the ongoing pandemic, addressing other critical public health challenges.
- CVSQIV & Flu SV mRNA - These are vaccine candidates for multivalent seasonal influenza and single antigen seasonal influenza, respectively. By targeting flu viruses, CureVac aspires to develop more effective and rapidly produced influenza vaccines, showing the versatility of mRNA technology in tackling various strains of influenza.
- CV8102 - Currently in Phase 1 clinical trial, CV8102 is being investigated for its efficacy in treating various forms of cancer, including melanoma, adenoidcystic carcinoma, as well as squamous cell cancer of the skin, head, and neck. This therapeutic candidate illustrates CureVac's venture into oncology, aiming to harness mRNA technology to stimulate the body's immune response against cancer cells.
- CVGBM - A specialized candidate focused on the treatment of cancer, showcasing CureVac's efforts to broaden its portfolio of innovative mRNA-based therapies targeting different cancers, demonstrating the broad potential application of its platform in oncology.
